Patents by Inventor Elbert Chin

Elbert Chin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTION
    Publication number: 20260152512
    Abstract: Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula (I): Wherein the variable substituents are described herein.
    Type: Application
    Filed: October 29, 2025
    Publication date: June 4, 2026
    Inventors: Elbert Chin, John O. Link, Ezra Roberts, James G. Taylor, Zheng-Yu Yang
  • HIV INHIBITOR COMPOUNDS
    Publication number: 20260132139
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: October 22, 2025
    Publication date: May 14, 2026
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Treo Martin, Zheng-Yu Yang
  • GLP-IR modulating compounds
    Patent number: 12570642
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: March 10, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • STAT6 COMPOUNDS
    Publication number: 20260042788
    Abstract: Modulators of signal transducer and activator of transcription 6 (STAT6) are provided, including compounds of Formula J, I and Ia, pharmaceutical compositions thereof, and methods of treating an inflammatory condition or disease.
    Type: Application
    Filed: July 17, 2025
    Publication date: February 12, 2026
    Inventors: Alexander J. Burckle, Elbert Chin, Yifan Deng, Deeba Ensan, Joshua D. Farr, Mary Stuart Herlihy, Benjamin J. June, Jagadeesh N. Manda, Gregory T. Notte, Eric Q. Parkhill, Dustin S. Siegel, Katie A. Spence, Zheng-Yu Yang, Xianhuang Zeng
  • PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
    Publication number: 20260035374
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.
    Type: Application
    Filed: August 21, 2025
    Publication date: February 5, 2026
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20250388585
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Application
    Filed: June 4, 2025
    Publication date: December 25, 2025
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Yifan Deng, Joshua D. Farr, Pancham Lal Gupta, Chao-I Hung, Benjamin J. June, Prasenjit K. Mukherjee, Shaina V. Nguyen, Gregory T. Notte, Daniel Roa, Adam J. Schrier, Katie A. Spence, Zheng-Yu Yang
  • GLP-1R modulating compounds
    Patent number: 12497382
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: May 10, 2023
    Date of Patent: December 16, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Tetracyclic compounds and methods for the treatment of Zika virus infection
    Patent number: 12497408
    Abstract: Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: December 16, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Elbert Chin, John O. Link, Ezra Roberts, James G. Taylor, Zheng-Yu Yang
  • HIV inhibitor compounds
    Patent number: 12479853
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: June 27, 2024
    Date of Patent: November 25, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • PRMT5 inhibitors and uses thereof
    Patent number: 12448388
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Grant
    Filed: May 14, 2024
    Date of Patent: October 21, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Yifan Deng, Joshua D. Farr, Pancham Lal Gupta, Chao-I Hung, Benjamin J. June, Prasenjit K. Mukherjee, Shaina V. Nguyen, Gregory T. Notte, Daniel Roa, Adam J. Schrier, Katie A. Spence, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20250312352
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: March 20, 2025
    Publication date: October 9, 2025
    Inventors: Megan K. Armstrong, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Chao-I Hung, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Pyrrolo[1,2-b]pyridazine derivatives
    Patent number: 12415808
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: September 16, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20250154172
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Application
    Filed: October 30, 2024
    Publication date: May 15, 2025
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Yifan Deng, Joshua D. Farr, Chao-I Hung, Benjamin J. June, Shaina V. Nguyen, Daniel Roa, Katie A. Spence, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20250099431
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
    Type: Application
    Filed: September 19, 2024
    Publication date: March 27, 2025
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-yu Yang
  • HIV INHIBITOR COMPOUNDS
    Publication number: 20250042910
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: June 27, 2024
    Publication date: February 6, 2025
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20240376110
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Application
    Filed: May 14, 2024
    Publication date: November 14, 2024
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Yifan Deng, Joshua D. Farr, Pancham Lal Gupta, Chao-I Hung, Benjamin J. June, Prasenjit K. Mukherjee, Shaina V. Nguyen, Gregory T. Notte, Daniel Roa, Adam J. Schrier, Katie A. Spence, Zheng-Yu Yang
  • GLP-1R modulating compounds
    Patent number: 12121511
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • HIV inhibitor compounds
    Patent number: 12084455
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: September 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Thiadiazole IRAK4 inhibitors
    Patent number: 12060351
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20240254118
    Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.
    Type: Application
    Filed: December 20, 2023
    Publication date: August 1, 2024
    Inventors: Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien, Joshua D. Farr, Pancham Lal Gupta, Chao-I Hung, Michael L. Mitchell, Prasenjit K. Mukherjee, Shaina V. Nguyen, Gregory T. Notte, Daniel Roa, Adam J. Schrier, Zheng-Yu Yang